Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of elritercept versus placebo in myelofibrosis-associated anemia on background ruxolitinib
2026-525660-17-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Elritercept + ruxolitinib with Placebo + ruxolitinib (2 arms). Primary endpoint: Red blood cell transfusion independence for at least 12 consecutive weeks. Planned start Oct 2026; status: authorised.
02
Drugs
elritercept
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2026-525660-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525660-17-00.